CNO Stock Analysis: CNO Financial | NYSE
Insurance - Life | NYSE, USA | Market Cap: 4.983m USD | 12M Return: 34.2% | US12621E1038 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 57.2M
EPS Trend: 86.5%
Qual. Beats: 1
Rev. Trend: 82.6%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
CNO Financial Group is a U.S. life and health insurer that develops, markets, and administers insurance and annuity products aimed primarily at middle-income pre-retiree and retired Americans. Its product portfolio spans Medicare supplement, supplemental health, long-term care insurance, Medicare advantage plans, fixed and fixed indexed annuities, and a range of life insurance products including universal life, whole life, term life, and graded benefit policies. Distribution occurs through phone, online, virtual, and face-to-face agent channels, as well as through workplace-based voluntary benefit programs sold to businesses, associations, and membership groups.
The company markets under three primary brands: Bankers Life, Washington National, and Colonial Penn. Founded in 1979 and headquartered in Carmel, Indiana, CNO has been publicly traded on the NYSE since 1987 and operates within the Life & Health Insurance sub-industry of the Financials sector. Its focus on the middle-income senior demographic distinguishes it from larger carriers that serve a broader or higher-net-worth customer base, with annuities and supplemental health products representing core sources of premium and fee income for this segment of the industry.
- Medicare supplement enrollment expands with aging middle-income population
- Fixed indexed annuity sales accelerate amid rising rate environment
- Long-term care reserve releases and share repurchases support capital returns
| Net Income: 279.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -0.13 > 1.0 |
| NWC/Revenue: -400.4% < 20% (prev -101.1%; Δ -299.3% < -1%) |
| CFO/TA 0.02 > 3% & CFO 698.9m > Net Income 279.6m |
| Net Debt (-4.96b) to EBITDA (733.6m): -6.76 < 3 |
| Current Ratio: 0.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (95.0m) vs 12m ago -7.88% < -2% |
| Gross Margin: 43.42% > 18% (prev 38.31%; Δ 5.12% > 0.5%) |
| Asset Turnover: 12.05% > 50% (prev 11.74%; Δ 0.31% > 0%) |
| Interest Coverage Ratio: 2.65 > 6 (EBIT TTM 571.7m / Interest Expense TTM 216.0m) |
| A: -0.47 (Total Current Assets 1.31b - Total Current Liabilities 19.9b) / Total Assets 39.8b |
| B: 0.06 (Retained Earnings 2.55b / Total Assets 39.8b) |
| C: 0.01 (EBIT TTM 571.7m / Avg Total Assets 38.6b) |
| D: 0.07 (Book Value of Equity 2.59b / Total Liabilities 37.3b) |
| Altman-Z'' = -2.69 = D |
| DSRI: 0.90 (Receivables 4.58b/4.78b, Revenue 4.65b/4.38b) |
| GMI: 0.88 (GM 38.31% / 43.42%) |
| AQI: 1.51 (AQ_t 0.97 / AQ_t-1 0.64) |
| SGI: 1.06 (Revenue 4.65b / 4.38b) |
| TATA: -0.01 (NI 279.6m - CFO 698.9m) / TA 39.8b) |
| Beneish M = -2.87 (Cap -4..+1) = A |
As of October 11, 2026, the stock is trading at USD 52.99 with a total of 665,268 shares traded. Over the past week, the price has changed by -1.62%, over one month by -2.98%, over three months by +0.44% and over the past year by +34.19%.
Current recommended Stop Loss: 50.50 (which is 4.7% or 2.3 ATR below the current price).
CNO Financial has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold CNO.
- StrongBuy: 0
- Buy: 0
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 53.8 | 1.4% |
P/E Trailing = 18.5724
P/E Forward = 9.7087
P/S = 1.0724
P/B = 1.9264
P/EG = 1.287
Revenue TTM = 4.65b USD
EBIT TTM = 571.7m USD
EBITDA TTM = 733.6m USD
Long Term Debt = 4.55b USD (from longTermDebt, last quarter)
Short Term Debt = unknown (none)
Debt = 4.55b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -4.96b USD (calculated: Debt 4.55b - CCE 9.52b)
Enterprise Value = 20.6m USD (4.98b + Debt 4.55b - CCE 9.52b)
Interest Coverage Ratio = 2.65 (Ebit TTM 571.7m / Interest Expense TTM 216.0m)
EV/FCF = 0.03x (Enterprise Value 20.6m / FCF TTM 698.9m)
FCF Yield = 3.39k% (FCF TTM 698.9m / Enterprise Value 20.6m)
FCF Margin = 15.04% (FCF TTM 698.9m / Revenue TTM 4.65b)
Net Margin = 6.02% (Net Income TTM 279.6m / Revenue TTM 4.65b)
Gross Margin = 43.42% ((Revenue TTM 4.65b - Cost of Revenue TTM 2.63b) / Revenue TTM)
Gross Margin QoQ = 43.42% (prev 44.63%)
Tobins Q-Ratio = 0.00 (Enterprise Value 20.6m / Total Assets 39.8b)
Interest Expense / Debt = 4.74% (Interest Expense 216.0m / Debt 4.55b)
Taxrate = 21.39% (76.1m / 355.7m)
NOPAT = 449.4m (EBIT 571.7m * (1 - 21.39%))
Current Ratio = 0.07 (Total Current Assets 1.31b / Total Current Liabilities 19.9b)
Debt / Equity = 1.76 (Debt 4.55b / totalStockholderEquity, last quarter 2.59b)
Debt / EBITDA = -6.76 (Net Debt -4.96b / EBITDA 733.6m)
Debt / FCF = -7.10 (Net Debt -4.96b / FCF TTM 698.9m)
Total Stockholder Equity = 2.58b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.73% (Net Income 279.6m / Total Assets 39.8b)
RoE = 10.82% (Net Income TTM 279.6m / Total Stockholder Equity 2.58b)
RoCE = 8.01% (EBIT 571.7m / Capital Employed (Equity 2.58b + L.T.Debt 4.55b))
RoIC = 2.29% (NOPAT 449.4m / Invested Capital 19.7b)
WACC = 5.93% (E(4.98b)/V(9.54b) * Re(7.94%) + D(4.55b)/V(9.54b) * Rd(4.74%) * (1-Tc(0.21)))
Discount Rate = 7.94% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.93 | Cagr: -6.65%
[DCF] Terminal Value 75.33% ; FCFF base≈701.1m ; Y1≈699.4m ; Y5≈731.3m
[DCF] Fair Price = 176.7 (EV 11.4b - Net Debt -4.96b = Equity 16.4b / Shares 92.5m; r=8.35% [WACC [floored]]; 5y FCF grow -0.78% → 2.50% )
EPS Correlation: 86.53 | EPS CAGR: 18.39% | SUE: 0.90 | # QB: 1
Revenue Correlation: 82.63 | Revenue CAGR: 4.07% | SUE: 1.17 | # QB: 1
EPS current Quarter (2026-09-30): EPS=1.09 | Chg30d=+2.83% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=4.67 | Chg30d=+5.47% | Revisions=+57% | GrowthEPS=+6.1% | GrowthRev=-10.5%
EPS next Year (2027-12-31): EPS=5.03 | Chg30d=+1.70% | Revisions=+57% | GrowthEPS=+7.7% | GrowthRev=+2.5%
[Analyst] Revisions Ratio: +58% (up=8, down=1)